Upload
amari-atnip
View
215
Download
1
Embed Size (px)
Citation preview
Management of Gastroenteropancreatic Neuroendocrine Tumour:an update
Joint Hospital Surgical Grand RoundDr Chan Kwan Kit
Caritas Medical Centre
Neuroendocrine Tumours (NETs)
Epithelial neoplasms with predominant neuroendocrine differentiation
Considered rare traditionally, comprising ~0.5% of all malignancies
Increasing incidence and prevalence, 2.5 -5/100,000 people per year Increasing awareness Improvement in diagnostic modalities
Distribution
Gastrointestinal tract: ~65% Bronchopulmonary system: ~25% Other locations ~10%:
thymus gonadsheart kidneysprostate
Classifications
WHO classification: tumour sitedegree of differentiation and grading functionality
TNM classification
Presentation
Asymptomatic Non-functional: non-specific symptoms
abdominal pain, small bowel obstruction, gastrointestinal bleeding, anorexia, weight loss
Functional: hormone/ peptides-related Serotonin: carcinoid syndrome Insulin: Whipple’s triad Gastrin Vasoactive intestinal peptide etc.
Investigation: biochemical markers
Specific markers depending on origin Urinary 5-hydroxyindoleacetic acid (5-HIAA):
main metabolite of serotoninGastrin InsulinGlucagon etc.
Investigation: biochemical markers
Chromogranin A Co-secreted by different neuroendocrine cell
types Correlates with tumour burden and stage Established roles in literatures:
Diagnosis Treatment response monitoring Relapse detection
Chromogranin A
Relatively high sensitivity 53-85%Ben L. Endocrinol Metab Clin N Am 40 (2011) 111–134
Non-specific Elevated in non-NETs condition:
Non-neoplastic: chronic atrophic gastritis; renal failure; liver cirrhosis
Neoplastic: HCC; colon cancers Drugs: proton pump inhibitors
Investigation: radiology
Computed tomography: arterial enhancing lesions with washout in
venous phase Magnetic resonance imaging:
more sensitive for liver and bone marrow metastases
Endoscopic ultrasound
High sensitivity for tumours at esophagus, stomach, duodenum, and pancreas
Allows image-guided biopsy
Octreoscan
Somatostatin (SST) receptor scintigraphy Principle: 80-90% of NETs express SST
receptors
Inflammatory lesions and some non-NET malignancies may give false positive results
Positron Emission Tomography
Ga-68 DOTATOC: high binding affinity for SST receptors
18-FDG: identifies clinically aggressive lesions with high metabolism
PET: pros and cons
Better spatial and contrast resolution giving higher sensitivity
Specific radioisotopes not widely available Hasn’t been fully validated with strong
evidence yet
Principle of imaging for GEPNETs
CT or MRI combining with functional imaging to obtain maximal information
Currently Octreoscan is still the gold standard for radionuclide imaging
Will likely be replaced by PET scan with specific radioisotopes
Management
Surgery remains the only curative treatment
Curative surgery should always be considered if feasible
Palliative surgery in metastatic disease:Debulking Resection of primary tumour
Proven benefit for local and hormonal symptom control
Surgery
Surgical plan dictated by:Tumour’s site of originDegree of tumour burdenGeneral health or debility of the patient
Operative consideration
Perioperative somatostatin analogsPrevents excessive hormone release during
manipulationParticularly important for intestinal carcinoids
Somatostatin (SST) analogs First line medication Acts through SST receptors on NETs
Inhibition of cellular proliferation and hormonal release
Available for clinical use: octreotide and lanreotide
SST analogs
Reduction in tumour size: <10% Stabilization of tumour: 40-60% Biochemical response: 50-70% Symptomatic response: 70-90%
Evidence of tumour response AND improvement of quality of life are well established
Alpha-Interferon (IFN)
Induces apoptosis Antiproliferative and anti-angiogenic
effects Evidence suggested usage in low-
proliferating NETs only
Radionuclide therapy:Radiolabelled SST analogs SST analogs, IFN,
chemotherapies, and external irradiation all have poor response in advanced or rapidly progressing GEPNETs
Radiolabelled SST analogs
GEPNETs: high level of SSTR expression and good vascularization
Studied radionuclide agents: 90Y-DOTA-octreotide 111In-pentetreotide 177Lu-DOTA-Tyr-octreotide
90Y-DOTA-octreotide
Encouraging short and intermediate term results: 23-28% objective response rate 63-70% symptomatic response rate Longer progression free survival for pancreatic NETs
Waldherr et al. J Nucl Med. 2002; 32:133-140
Paganelli G et al. Biopolymers 2008; 66: 393-398
No long term result available yet
Cytotoxic chemotherapy
Sensitivity of NETs correlates with primary tumour location and tumour grade low grade carcinoid tumours typically resistant
First line therapy only for metastatic/ unresectable pancreatic NETs combination of streptozotocin and 5-fluorouracil (5-
FU)
Some evidence for use in high grade ileal NETs
Targeted therapy
Mammalian target of rapamycin (mTOR): serine kinase regulating cell growth and proliferation
mTOR inhibitor: everolimus Two recently completed phase III studies (RADIANT 2
and RADIANT 3) demonstrated statistically significant improvement in progression-free survival (PFS) in metastatic carcinoid tumours
Targeted therapy
NETs are highly vascular and frequently overexpress VEGF ligand and receptor
Bevacizumab and sunitinib: VEGF inhibitors
Phase II studies for both agents are promising
Multinational phase III study ongoing
Liver-directed therapies
Liver is the predominant site of metastases for GEPNETs
Metastatic liver disease gives more carcinoid syndrome
Treatment options:Liver resection/ ablationHepatic artery embolization
Liver resection/ ablation
Advocated if more than 90% of tumours can be successfully resected or ablated
Symptom palliation and survival prolongation well reported
Hepatic artery embolization
Diffuse unresectable liver metastases
Rationale: tumours derived majority of their blood supply from arterial circulation
Bilobar metastases: staged lobar embolization at 4-6 weeks interval
Conclusion
GEPNETs represent a complex and heterogenous tumour entity with rising incidence and prevalence
Diagnostic and therapeutic challenges due to its relative rarity
Conclusion
Diagnostic and treatment options for GEPNETs are expanding
Controversies exist for choice and sequencing of treatments requiring relevant expertise input
Multidisciplinary approach warranted for best outcome for patients
Investigation: biochemical markers
Urinary 5-hydroxyindoleacetic acid (5-HIAA) Main metabolite of serotonin
helps diagnosing carcinoid syndrome
Not applicable for non-functional tumours
Operative consideration (2)
Role of prophylactic cholecystectomyRationale: somatostatin analogs treatment
leads to development of gallstonesHowever most of these stones are
asymptomaticNo conclusive evidence to recommend
prophylactic cholecystectomy
Side effects of SST analogs
Usually mild: flatulence; abdominal pain; diarrhea in less than 10% patients
Choledolithiasis: in 20-40% patients with long term SST analogs; acute symptoms rare
SST analogs + IFN
Combination therapy as upfront treatment in therapy-naïve patients is not well established
Evidence for additive effect of tumour response: sequential use of the two drugs; and, combination after progression with single agent
No proven survival benefit
Side effect profile (Radiolabelled SST analogs) Toxic effects are mild in most patients Nausea and vomiting being the commonest
symptoms Severe lymphopenia and renal toxicity have
been reported
Waldherr et al. J Nucl Med. 2002; 32:133-140
Paganelli G et al. Biopolymers 2002; 66: 393-398
De Jong M et al. Int J Cancer 2001 Jun 1; 92(5): 628-33
Ebrahim S et al. Cancer biotherapy and radiopharmaceuticals Vol 23, No. 3, 2008
Hepatic artery embolization
Contraindication:Poor liver functionModerate to severe ascitesPortal venous thrombosis